ICD-coded information on sites of metastasis in oncology real-world data is specific but not sensitive Published May 2018 Citation Parrinello, C.M., Seidl-Rathkopf, K.N., Bennette, C, Bourla, A.B., Nussbaum, N.C., Carson, K.R., Abernethy, A.P. . ISPOR Annual Meeting. . https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-com-pdf/Sites-of-Mets-Structured-vs-Unstructured-ISPOR-2018-Poster_Vertical_Final_MM.pdf Authors: Sources:ISPOR Annual Meeting Share Posted inPublications More publicationsESMOOctober 2025Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practiceBrufsky A, Layman R, Liu X, et al.Publication summaryPublicationsComparative effectivenessBreast cancerESMOOctober 2025Real-world treatment patterns and outcomes in US patients with neurotrophic tyrosine receptor kinase–positive solid tumorsSu, I, Flores Avile C, Huang P, et al. Publication summaryPublicationsTreatment patternsESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancer